Cannabidivarin clinical trials
Also written CBDV and GWP42006.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses cannabidivarin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 3
Jazz Pharmaceuticals (4) · Montefiore Medical Center (1) · King's College London (1) · Eric Hollander (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses cannabidivarin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)CompletedPhase 2Montefiore Medical CenterNCT03202303Written as CannabidivarinHow we know
- CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)TerminatedPhase 2Eric HollanderNCT03848481Written as CBDV CompoundHow we know
- Shifting Brain Excitation-Inhibition Balance in Autism Spectrum DisorderCompletedNot applicableKing's College LondonNCT03537950Written as CBDVHow we know
- A Study of the Safety and Tolerability of GWP42006 in Healthy SubjectsCompletedPhase 1Jazz PharmaceuticalsNCT01918735Written as GWP42006How we know
- A Study of GWP42006 in People With Focal Seizures - Part BCompletedPhase 2Jazz PharmaceuticalsNCT02365610Written as GWP42006How we know
- A Study of GWP42006 in People With Focal Seizures - Part ACompletedPhase 2Jazz PharmaceuticalsNCT02369471Written as GWP42006How we know
- Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum DisorderTerminatedPhase 2Jazz PharmaceuticalsNCT03849456Written as GWP42006How we know
Codes
What other systems call cannabidivarin · ClinicalTrials.gg INT006269
- MeSH (NLM) C580853cannabidivarinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) I198VBV98ICANNABIDIVARINConfirmed NLM, Wikidata
- Wikidata Q76421750CannabidivarinConfirmed NLM, Wikidata
- DrugBank DB14050One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C580853 | cannabidivarin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | I198VBV98I | CANNABIDIVARIN | Confirmed NLM, Wikidata |
| Wikidata | Q76421750 | Cannabidivarin | Confirmed NLM, Wikidata |
| DrugBank | DB14050 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.